Yes, of course; the salient points are that Viekira doesn't require ribavirin for GT1b patients (as it does for GT1a) and that Viekira has somewhat better efficacy than Zepatier.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”